BACKGROUND: The aim of this retrospective study was to evaluate the significance of pre-treatment levels of peripheral blood lymphocyte subsets for survival of renal cell carcinoma (RCC) patients treated with interferon-a2b (IFN). PATIENTS AND METHODS: CD3+, CD19+, CD16&56+, CD4+, CD8+, CD4+CD45ROhigh and CD8highCD57+ lymphocyte subsets in peripheral blood of 85 advanced RCC patients were determined using flow cytometry. The survival of IFN-treated and non-treated patients was analyzed by gradually testing different cut-off levels of each lymphocyte subset. RESULTS: Advanced RCC patients with > or = 30% CD8highCD57+ lymphocytes in the CD8+ subset had shorter survival compared to patients with < 30% CD8highCD57+ lymphocytes in the CD8+ subset (p = 0.01). Treatment with IFN increased overall survival only in the former subgroup of RCC patients (p = 0.02). CONCLUSION: The present study suggests that the percentage of CD8highCD57+ lymphocytes in the CD8+ subset may have a prognostic significance for advanced RCC patients and may have a predictive value in patient selection for survival benefit due to treatment with IFN.
BACKGROUND: The aim of this retrospective study was to evaluate the significance of pre-treatment levels of peripheral blood lymphocyte subsets for survival of renal cell carcinoma (RCC) patients treated with interferon-a2b (IFN). PATIENTS AND METHODS: CD3+, CD19+, CD16&56+, CD4+, CD8+, CD4+CD45ROhigh and CD8highCD57+ lymphocyte subsets in peripheral blood of 85 advanced RCCpatients were determined using flow cytometry. The survival of IFN-treated and non-treated patients was analyzed by gradually testing different cut-off levels of each lymphocyte subset. RESULTS: Advanced RCCpatients with > or = 30% CD8highCD57+ lymphocytes in the CD8+ subset had shorter survival compared to patients with < 30% CD8highCD57+ lymphocytes in the CD8+ subset (p = 0.01). Treatment with IFN increased overall survival only in the former subgroup of RCCpatients (p = 0.02). CONCLUSION: The present study suggests that the percentage of CD8highCD57+ lymphocytes in the CD8+ subset may have a prognostic significance for advanced RCCpatients and may have a predictive value in patient selection for survival benefit due to treatment with IFN.
Authors: Richard C Wu; Shujuan Liu; Jessica A Chacon; Sheng Wu; Yufeng Li; Pariya Sukhumalchandra; James L Murray; Jeffrey J Molldrem; Patrick Hwu; Hanspeter Pircher; Gregory Lizée; Laszlo G Radvanyi Journal: Clin Cancer Res Date: 2012-02-03 Impact factor: 12.531
Authors: Jonathan M Weiss; W Gregory Alvord; Octavio A Quiñones; Jimmy K Stauffer; Robert H Wiltrout Journal: Hum Immunol Date: 2014-05-04 Impact factor: 2.850